Kemnay Advisory Services’s Neurocrine Biosciences NBIX Stock Holding History

Kemnay Advisory Services’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$5.27K	Buy	+40	New	+$5.31K	﹤0.01%	1162
2020 Q3	–	Sell	-4,292	Closed	-$524K	–	93
2020 Q2	$524K	Sell	4,292 -5,676	-57%	-$627K	0.08%	62
2020 Q1	$863K	Sell	9,968 -8,172	-45%	-$800K	0.24%	33
2019 Q4	$1.95M	Buy	+18,140	New	+$1.9M	0.48%	35

Other funds holding NBIX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Kemnay Advisory Services's NBIX Position: Q1 2026 in Review

Kemnay Advisory Services opened a new position in Neurocrine Biosciences (NBIX) in Q1 2026: 40 shares worth $5.27K. The stake represents ﹤0.01% of the portfolio and ranks #1162 among its holdings. This is a return to the name: Kemnay Advisory Services previously reported a position in NBIX as recently as Q2 2020.

Kemnay Advisory Services first reported a position in NBIX in Q4 2019 and has held it in 4 quarters since. The position peaked at $1.95M in Q4 2019. 695 funds tracked by Wall St. Rank hold NBIX as of Q1 2026.

Kemnay Advisory Services held 40 shares of Neurocrine Biosciences worth $5.27K as of Q1 2026.
Neurocrine Biosciences was a new Kemnay Advisory Services position in Q1 2026.
Neurocrine Biosciences made up ﹤0.01% of Kemnay Advisory Services's portfolio in Q1 2026, its #1162 holding.
Kemnay Advisory Services first reported a position in Neurocrine Biosciences in Q4 2019 and has held it in 4 quarters since.
Kemnay Advisory Services's Neurocrine Biosciences position peaked at $1.95M in Q4 2019.
695 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2026.

Based on Kemnay Advisory Services's 13F filing for Q1 2026, filed 15 May 2026.